Mannitolo Fresenius Kabi Italia

Mannitol, the active ingredient in Mannitolo Fresenius Kabi Italia, is an excipient presented as a solution for injection for intravenous use. It reduces intracranial pressure, promotes diuresis in acute renal failure, and serves as a solvent for intravenous drug formulations.

GNH USA supplies Mannitolo Fresenius Kabi Italia as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Mannitol is employed as an osmotic agent in several clinical situations.

Intracranial hypertension: reduces intracranial pressure by drawing fluid from the brain into the vascular compartment. Acute renal failure: promotes diuresis to aid fluid removal and electrolyte balance. Intravenous drug formulation: acts as an isotonic solvent for the preparation of various injectable medicines.

Mannitol may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Headache: mild to moderate intensity. - Nausea or vomiting: transient gastrointestinal upset. - Electrolyte imbalance: especially hyponatremia or hypokalemia. - Hypotension: due to rapid plasma volume expansion. - Tachycardia: secondary to volume shifts.

Serious or Rare Side Effects: - Pulmonary edema: fluid overload in susceptible patients. - Severe electrolyte disturbances: can precipitate cardiac arrhythmias. - Anaphylactic reaction: rare but potentially life‑threatening. - Acute renal failure: paradoxical worsening in patients with pre‑existing kidney disease.

Mannitol administration requires careful clinical monitoring.

Monitor serum electrolytes: check sodium, potassium, and osmolality regularly. Assess intracranial pressure: ensure appropriate indication and response. Use caution in renal impairment: adjust infusion rate or avoid if severe. Avoid rapid infusion: infuse over recommended time to prevent hemodynamic shifts. Adjust dose in heart failure: consider reduced volume tolerance. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Mannitol can alter the pharmacodynamics of several drugs.

Major Interactions (Avoid): - Lithium: increased risk of lithium toxicity due to altered renal clearance. - Digoxin: electrolyte shifts may predispose to digoxin toxicity. - Loop diuretics: additive diuretic effect may cause severe volume depletion.

Moderate Interactions (Monitor Closely): - Insulin: rapid shifts in plasma volume can affect glucose control. - NSAIDs: may blunt the diuretic response of mannitol. - Antihypertensives: additive hypotensive effect requires blood pressure monitoring.